Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19409565 | 0.99 | HTR2C (0.37) | HTR2CHTR2AKDM1ADRD2MKNK1 | |
| SCHEMBL2589530 | 0.83 | PNMT (0.36) | HTR2CHTR2ASLC6A4HTR2B | |
| SCHEMBL19030789 | 0.79 | HIF1A (0.36) | HTR2CHTR2AKDM1ADRD2AKR1B1 | |
| SCHEMBL21985303 | 0.75 | HTR2C (0.42) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19409643 | 0.72 | HRH3 (0.44) | — | |
| SCHEMBL15724661 | 0.72 | AKR1B1 (0.46) | HTR2ADRD2AKR1B1 | |
| SCHEMBL3859304 | 0.72 | HTR2C (0.49) | HTR2CHTR2ADRD2 | |
| SCHEMBL30529385 | 0.72 | HTR2C (0.49) | HTR2CHTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL4214755 | 0.71 | HTR2C (0.48) | HTR2CHTR2ADRD2 | |
| Bromide SCHEMBL5772502 | 0.71 | HTR2C (0.48) | HTR2CHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715613-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | HTR2C 572/4885HTR2A 826/4885KDM1A 2299/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | HTR2C 572/4885HTR2A 826/4885KDM1A 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.